Merit Medical Systems, Inc. (MMSI)

NASDAQ: MMSI · Real-Time Price · USD
93.95
-1.71 (-1.79%)
May 5, 2025, 4:00 PM EDT - Market closed
-1.79%
Market Cap 5.55B
Revenue (ttm) 1.39B
Net Income (ttm) 122.26M
Shares Out 59.10M
EPS (ttm) 2.04
PE Ratio 46.08
Forward PE 28.11
Dividend n/a
Ex-Dividend Date n/a
Volume 447,823
Open 94.85
Previous Close 95.66
Day's Range 93.96 - 95.39
52-Week Range 78.73 - 111.45
Beta 0.70
Analysts Buy
Price Target 109.00 (+16.02%)
Earnings Date Apr 24, 2025

About MMSI

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bo... [Read more]

Sector Healthcare
IPO Date Aug 9, 1990
Employees 7,400
Stock Exchange NASDAQ
Ticker Symbol MMSI
Full Company Profile

Financial Performance

In 2024, Merit Medical Systems's revenue was $1.36 billion, an increase of 7.89% compared to the previous year's $1.26 billion. Earnings were $120.36 million, an increase of 27.48%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MMSI stock is "Buy." The 12-month stock price forecast is $109.0, which is an increase of 16.02% from the latest price.

Price Target
$109.0
(16.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. In the AVG cohort of the US pivota...

19 hours ago - GlobeNewsWire

Merit Medical Systems, Inc. (MMSI) Q1 2025 Earnings Call Transcript

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q1 2025 Results Conference Call April 24, 2025 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Raul Parra - C...

11 days ago - Seeking Alpha

Merit Medical Launches the Ventrax™ Delivery System

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardia Novel all-in-one retrograde aortic access delivery system supports streamlined treat...

26 days ago - GlobeNewsWire

Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025

SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will rel...

4 weeks ago - GlobeNewsWire

Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of G...

5 weeks ago - GlobeNewsWire

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomi...

5 weeks ago - GlobeNewsWire

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred L...

6 weeks ago - GlobeNewsWire

Merit Medical: A Success Story That Keeps Getting Better

Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best...

7 weeks ago - Seeking Alpha

First Patient Enrolled in Merit Medical's PREEMIE Study

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants Multicenter, prospective study de...

2 months ago - GlobeNewsWire

Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript

Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript

2 months ago - Seeking Alpha

Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance

Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10...

2 months ago - GlobeNewsWire

Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025

* Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading “Non-GAAP F...

4 months ago - GlobeNewsWire

Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY...

4 months ago - GlobeNewsWire

Merit Medical Announces Resignation of President, Joseph Wright

SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today announced the resignation o...

5 months ago - GlobeNewsWire

Fundus Camera Market Global Forecasts and Company Analysis 2025-2033, Profiles of Carl Zeiss Medites, Topcon Medical Systems, Merit Medical Systems, NIDEK, and Revenio Group

Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Fundus Camera Market Global Forecast Report by Product Type, End-User, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMark...

5 months ago - GlobeNewsWire

Merit Medical's WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm c...

5 months ago - GlobeNewsWire

Merit Medical Completes Acquisition of Lead Management Portfolio from Cook Medical

SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook...

6 months ago - GlobeNewsWire

Merit Medical Systems, Inc. (MMSI) Q3 2024 Earnings Call Transcript

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman & Chief Executive Officer Brian Lloyd...

6 months ago - Seeking Alpha

Merit Medical Systems to Announce Third Quarter 2024 Results on October 30, 2024

SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will rele...

7 months ago - GlobeNewsWire

Merit Medical Signs Agreement to Purchase Lead Management Portfolio from Cook Medical

SOUTH JORDAN, Utah, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced it has signed a definitive asset purchase a...

8 months ago - GlobeNewsWire

Merit Medical's WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients

In the US pivotal trial, WRAPSODY achieved 89.8% target lesion primary patency at 6 months In the US pivotal trial, WRAPSODY achieved 89.8% target lesion primary patency at 6 months

8 months ago - GlobeNewsWire

Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress

SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians ...

8 months ago - GlobeNewsWire

Merit Medical Systems, Inc. (MMSI) Q2 2024 Earnings Call Transcript

Merit Medical Systems, Inc. (NASDAQ:MMSI) Q2 2024 Results Conference Call August 1, 2024 5:00 PM ET Company Participants Fred Lampropoulos - Founder, Chairman, and Chief Executive Officer Brian Lloyd...

9 months ago - Seeking Alpha

Merit Medical Reports Second Quarter 2024 Results and Raises Full-Year Guidance

Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6% Constant currency revenue* up 6.6% Constant currency revenue, organic,* up 5.0% GAAP operating margin of 13.6%, compared to ...

9 months ago - GlobeNewsWire

Merit Medical to Present 6-Month Outcomes from Randomized Arm of WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study at Two Upcoming Medical Meetings

SOUTH JORDAN, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced plans to release findings from its WAVE stud...

9 months ago - GlobeNewsWire